摘要
目的:鉴定肿瘤抗原MAGE－A3新的HLA-A2限制性CTL表位。方法:采用CTL表位预测的基序法与二级锚点相结合预测 MAGE-A3的 HLA-A2限制性CTL表位;用计算机分子模拟进行表位的初步筛选;以标准51Cr释放试验检测特异性CTLs诱导活性。结果:在所筛选的4个候选CTL表位中,MAGE-A3201-209可在体外有效诱导特异性CTLs的产生,杀伤靶细胞。结论:MAGE-A3201-209为肿瘤抗原MAGE-A3的新的HLA-A2限制性CTL表位。为基于MAGE-A3的肿瘤治疗性多肽疫苗的设计、研究奠定了基础。
To identify novel HLA-A2-restricted CTL epitopes derived from the tumor antigen MAGE-A3.Methods:The CTL epitope candidates were predicted by using the motif prediction method combined with the secondary anchor residues plot. It was established that the molecule model of CIL epitope candidates bound to the HLA-A2 molecule and of the HLA-A2-peptide complex by molecule modeling. Four selected candidates were assayed by the standard 51 Cr release assay to determine their abilities of inducing the generation of specific CTLs. Results: Among them, the pepnde MAGE-A3201-209 could effectively induce specific Oils and the CITs could lyse not only the melanoma cell line LB373-MEL but also the murine mastocytoma cell line genetically modified with the human HLA-A2 gene and pulsed with MAGE-A32oi.2cs ? Conclusion; MAGE-AS201-209 is a novel CTL epitope presented by HLA-A2. This study provides experimental basis for design and study of tumor therapeutic peptide vaccines based on the tumor antigen MAGE-A3.
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2002年第1期26-29,共4页
Chinese Journal of Immunology
基金
国家自然科学基金资助项目(批准号:39900134)
